Treatment of lower respiratory tract infection with tradipitant
Grant
US12582640B2
Kind: B2
Mar 24, 2026
Assignee
Vanda Pharmaceuticals Inc.
Inventors
Mihael H. Polymeropoulos, Christos Polymeropoulos, Vasilios Polymeropoulos, Changfu Xiao
Abstract
Disclosed herein is a method of treatment of a lower respiratory tract infection caused by, e.g., coronavirus disease (COVID-19), influenza, or other virus, comprising treatment with the NK-1 receptor antagonist, tradipitant.
CPC Classifications
A61K 31/444
A61K 31/454
Filing Date
2021-03-24
Application No.
17906861
Claims
20